1 March 2021 in Diabetic Medicine
Aims: Restrictions during the COVID‐19 crisis will have impacted on opportunities to be active. We aimed to (a) quantify the impact of COVID‐19 restrictions on accelerometer‐assessed physical activity and sleep in people with type 2 diabetes and (b) identify predictors of physical activity during COVID‐19 restrictions.Methods: Participants were from the UK Chronotype of Patients with type 2 diabetes and Effect on Glycaemic Control (CODEC) observational study. Participants wore an accelerometer on their wrist for 8 days before and during COVID‐19 restrictions. Accelerometer outcomes included the following: overall physical activity, moderate‐to‐vigorous physical activity (MVPA), time spent inactive, days/week with ≥30‐minute continuous MVPA and sleep. Predictors of change in physical activity taken pre‐COVID included the following: age, sex, ethnicity, body mass index (BMI), socio‐economic status and medical history.Results: In all, 165 participants (age (mean±S.D = 64.2 ± 8.3 years, BMI=31.4 ± 5.4 kg/m2, 45% women) were included. During restrictions, overall physical activity was lower by 1.7 mg (~800 steps/day) and inactive time 21.9 minutes/day higher, but time in MVPA and sleep did not statistically significantly change. In contrast, the percentage of people with ≥1 day/week with ≥30‐minute continuous MVPA was higher (34% cf. 24%). Consistent predictors of lower physical activity and/or higher inactive time were higher BMI and/or being a woman. Being older and/or from ethnic minorities groups was associated with higher inactive time.Conclusions: Overall physical activity, but not MVPA, was lower in adults with type 2 diabetes during COVID‐19 restrictions. Women and individuals who were heavier, older, inactive and/or from ethnic minority groups were most at risk of lower physical activity during restrictions.
19 October 2014 in European Journal of Applied Physiology
1 February 2016 in Medicine & Science in Sports & Exercise
Ingestion of tyrosine (TYR), a catecholamine precursor, has previously improved aspects of cognitive function and mood during acute stress, although there is limited research exploring the optimal dose relative to blood values. The serum responses of two doses of TYR were investigated (study 1), with the identified "optimal" dose assessed relative to cognitive and physical performance during a military-based protocol in the heat (study 2). For study 1, 21 participants were assigned to one of the following three groups: HIGH (two doses of 150 mg · kg(-1) body mass TYR), LOW (two doses of 75 mg · kg(-1) body mass TYR), and CON (sugar-free drink). Participants ingested TYR in two separate doses (0900 and 1300 h) and remained in the laboratory from 0800 to 1700 h, having blood drawn every hour. For study 2, eight participants completed a military-based load carriage protocol composed of a 60-min walk (6.5 km · h(-1)) followed by a 2.4-km time trial carrying a 25-kg backpack (40°C; relative humidity, 30%) on two occasions (TYR/placebo) in a double-blind counterbalanced crossover design. Cognitive function was assessed before, during, and after exercise. Study 1 demonstrated that ingestion of a single dose of 150 mg · kg(-1) body mass TYR was equally efficient at elevating serum TYR concentration relative to a double dose. In study 2, exercise heat stress impaired some aspects of cognitive function; however, TYR did not alleviate these decrements (P > 0.05). Furthermore, no difference was observed in any physiological variable between conditions (P > 0.05) or time trial completion time (P = 0.74) between TYR (19.78 ± 3.44 min) and placebo (20.29 ± 3.55 min). Despite marked elevations in serum TYR concentration, ingestion of TYR did not influence cognitive function or physical performance during exercise heat stress.
1 February 2022 in Journal of Thermal Biology
14 September 2015 in Extreme Physiology & Medicine